NULISAseq™ CNS Disease Panel 120

Robust Profiling of CNS Disease
at the Lowest Limit of Detection


from as little as
10uL of sample


to measure proteins
at fg/mL levels


to see biomarkers
other technologies miss

12 logs
Dynamic Range

without dilution


with <10% intra- and
inter-plate CV

Proteomics is emerging as a vital tool in identifying biomarkers of neurodegenerative disease progression and response to therapy. In collaboration with eminent neuroscience investigators, we developed the most relevant and comprehensive CNS disease panel. The NULISASeq™ CNS Disease Panel 120 provides best-in-class sensitivity and robust, multiplexed analysis of 120 neuro-specific and inflammatory proteins from 10 µl of plasma or CSF. Scientists can reliably and precisely detect critical biomarkers—including pTau-217, GFAP, NfL, and alpha-synuclein—measure changes in key inflammatory pathways, and support protein biomarker discovery and validation studies that may ultimately improve patient outcomes.

The NULISASeq™ CNS Disease Panel 120 simultaneously profiles 120 proteins associated with a broad spectrum of neurodegenerative disorders, empowering researchers to obtain comprehensive, actionable insights faster than ever before. Combining unmatched sensitivity, broad dynamic range, and unparalleled multiplexing, NULISASeq maximizes the biomarker potential of precious specimens, ensuring target detection regardless of abundance.

Alamar Biosciences invites you to be at the forefront of neurological research innovation. Embrace the power of comprehensive protein biomarker detection with the NULISAseq™ CNS Disease Panel 120.

Read the seminal NULISA publication in Nature Communications

NULISA: A Novel Proteomic Liquid Biopsy Platform With Attomolar Sensitivity And High Multiplexing

CNS Disease Panel Content

Profile 120+ biomarkers of CNS Disease from a single 10µl sample

Use mouse scroller or finger to zoom in/out. 

Explore the Panel Content

Profile ~120 biomarkers of CNS Disease from a single 10µl sample.

Access today through our Technology Access Program

FOR RESEARCH USE ONLY. Not for use in diagnostic procedures.